Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: A multicentre study

BJU International

Volumn 97, Issue 4, 2006, Pages 742-746

  Chung, Byung Ha ^a,d   Hong, Sung Joon ^a   Cho, Jin Seon ^b   Seong, Do Hwan ^c  

^a Yonsei University College of Medicine   (South Korea)

^b Hallym University   (South Korea)

^c Inha University   (South Korea)

^d Yonsei University   (South Korea)

Author keywords

BPH; Prediction; Prostate volume; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CAUCASIAN; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; RACE DIFFERENCE; SYMPTOMATOLOGY; TUMOR VOLUME; URINARY TRACT INFECTION; URINE FLOW RATE;

AGED; HUMANS; KOREA; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; SENSITIVITY AND SPECIFICITY;

EID: 33644890470     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06016.x     Document Type: Article

References (23)

1. Jacobsen SJ Jacobson DJ Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention J Urol 1997 158 481 7
2. Roehrborn CG McConnell JD Lieber M et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group Urology 1999 53 473 80
3. Boyle P Gould AL Roehrborn CG Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials Urology 1996 48 398 405
4. Roehrborn CG Malice M Cook TJ Girman CJ Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials Urology 2001 58 210 6
5. Roehrborn CG Boyle P Bergner D et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group Urology 1999 54 662 9
6. McConnell JD Bruskewitz R Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group N Engl J Med 1998 338 557 63
7. Hong SJ Ko WJ Kim SI Chung BH Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study Eur Urol 2003 44 94 100
8. Roehrborn CG Boyle P Gould AL Waldstreicher J Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia Urology 1999 53 581 9
9. Bo M Ventura M Marinello R Capello S Casetta G Fabris F Relationship between prostatic specific antigen (PSA) and volume of the prostate in benign prostatic hyperplasia in the elderly Crit Rev Oncol Hematol 2003 47 207 11
10. Mochtar CA Kiemeney LA van Riemsdijk MM et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia Eur Urol 2003 44 695 700
11. Hochberg DA Armenakas NA Fracchia JA Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia Prostate 2000 45 315 9
12. Blijenberg BG Yurdakul G Van Zelst BD Bangma CH Wildhagen MF Schroder FH Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer BJU Int 2001 88 545 50
13. Blijenberg BG Storm BN van Zelst BD Kruger AE Schroder FH New developments in the standardization of total prostate-specific antigen Clin Biochem 1999 32 627 34
14. Tewari A Indudhara R Shinohara K et al. Comparison of transrectal ultrasound prostatic volume estimation with magnetic resonance imaging volume estimation and surgical specimen weight in patients with benign prostatic hyperplasia J Clin Ultrasound 1996 24 169 74
15. Bosch JL Hop WC Bangma CH Kirkels WJ Schroder FH Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism Prostate 1995 27 241 9
16. Di Silverio F Sciarra A D'Eramo G Casale P Loreto A Seccareccia F Relationship among age, prostate-specific antigen, and prostate volume in men with lower urinary tract symptoms (LUTS) and in different groups of men with and without benign and malignant prostate diseases Prostate 1998 36 1 7
17. Partin AW Carter HB Chan DW et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia J Urol 1990 143 747 52
18. Gormley GJ Stoner E Bruskewitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group N Engl J Med 1992 327 1185 91
19. The Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia Prostate 1993 22 291 9
20. Andersen JT Ekman P Wolf H et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group Urology 1995 46 631 7
21. Lepor H Auerbach S Puras-Baez A et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia J Urol 1992 148 1467 74
22. Nickel JC Fradet Y Boake RC et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study CMAJ 1996 155 1251 9
23. Marberger MJ Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group Urology 1998 51 677 86